Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner

Sun Young Joo, Kyung Ah Cho, Yun Jae Jung, Han Seong Kim, Seong Yeol Park, Yong Bock Choi, Kyeong Man Hong, So Youn Woo, Ju Young Seoh, Su Jin Cho, Kyung Ha Ryu

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Background aims. Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic cell transplantation (HCT). Recent literature demonstrates a potential benefit of human mesenchymal stromal cells (MSC) for the treatment of refractory GvHD; however, the optimal dose remains uncertain. We set out to develop an animal model that can be used to study the effect of MSC on GvHD. Methods. A GvHD mouse model was established by transplanting C3H/he donor bone marrow (BM) cells and spleen cells into lethally irradiated BALB/c recipient mice. MSC were obtained from C3H/he mice and the C3H/10T1/2 murine MSC line. Results. The mRNA expression of Foxp3 in regional lymph nodes (LN) localized with T cells was markedly increased by the addition of C3H10T1/2 cells in a real-time polymerase chain reaction (PCR). Using a mixed lymphocyte reaction, we determined the optimal splenocyte proliferation inhibition dose (MSC:splenocyte ratios 1:2 and 1:1). Three different C3H10T1/2 cell doses (low, 0.5 × 106, intermediate, 1 × 10 6, and high, 2 × 106) with a consistent splenocyte dose (1 × 106) were evaluated for their therapeutic potential in an in vivo GvHD model. The clinical and histologic GvHD score and KaplanMeier survival rate were improved after MSC transplantation, and these results demonstrated a dose-dependent inhibition. Conclusions. We conclude that MSC inhibit GvHD in a dose-dependent manner in this mouse model and this model can be used to study the effects of MSC on GvHD.

Original languageEnglish
Pages (from-to)361-370
Number of pages10
Issue number3
StatePublished - 2010

Bibliographical note

Funding Information:
This research was supported by a grant (08172 KFDA304) from the Korea Food and Drug Administration in 2008.


  • Graft-versus-host disease
  • Mesenchymal stromal cells
  • Mouse model
  • Optimal dose


Dive into the research topics of 'Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner'. Together they form a unique fingerprint.

Cite this